. As HIV, HBV and HCV often share same routes of transmission, co-infections are common, and these confections can greatly increase disease progression. One such co-infection that is often missed is HIV with occult HBV infection, which is defined as the presence of HBV DNA in serum or liver despite the absence of HBsAg in the blood.
(YRG CARE) for HIV testing between 2009 and 2010 (n = 502). No participant had past history of HBV vaccination. Samples collected from the participants were processed within 6 hours and stored at −75°C till testing. At the time of testing, each untouched aliquot was retrieved from the freezer and thawed once prior to serological testing and NAT. The study was approved by the institutional review board (IRB) of YRG CARE and UCSD.
| Laboratory assays
HBsAg ELISA was performed using Genedia HBsAg ELISA 3.0, and anti-HCV ELISA was performed using Genedia HCV ELISA 3 
| Pooling NAT (PCR) to identify occult HBV infection
As HBV infection can be missed with the serological tests described above, we evaluated the use of minipool HBV NAT to identify "Occult HBV" infection, which is defined as HBsAg negative and HBV DNA positive. To try to increase testing efficiency, we applied minipool methods, as previously described 8, 9 with slight modifications. Briefly, minipools of five plasma samples were prepared by combining 200 μL from each sample, constituting 1000 μL of sample in each minipool.
Sample selection for constructing minipools was random, and the assay performer was blinded to the already available HBV viral load results. To test the minipool, 500 μL from each pool was then tested for HBV DNA by Abbott RealTime PCR. If any minipool was found to be positive, each sample in the pool was individually deconvoluted, as per Dorfmann's method 10 Results from minipool testing were compared to individual testing from each person's sample to determine the test characteristics of the minipool NAT ( Figure S1 ).
| Cost analysis
Cost-effectiveness was evaluated by the following formula: (Table 1) .
| Statistical analysis

| Occult HBV
We randomly selected serum samples from 270 HBsAg-negative HIV-
positive participants and these were tested for HBV DNA with the Abbott HBV DNA RealTime viral load assay, to identify occult HBV infection. Twenty-seven (10%) were found to have occult HBV, with median HBV viral load of 37 IU mL −1 (IQR 21-131 IU mL anti-HBs was significantly associated with occult HBV infection (P < .05) (Table 1) . Further, among those with occult HBV, none were positive for HDV and 25 (92.6%) were positive for anti-HCV.
| Prediction of occult HBV prevalence, by selecting samples based on serological markers
In this study, we selected HBsAg-negative samples for occult HBV iden- If anti-HBs-positive persons were also selected for occult HBV identification, seven additional people who have been identified (Table 2 ).
| Minipool NAT to identify Occult HBV infection
To identify occult HBV infection using the minipool strategy, we (Table 3) , so the cost saving was 56%.
| DISCUSSION
As HBV infection is known to have a negative impact on HIV infection by doubling the events of AIDS or death, 12 we investigated HBV infection among individuals with HIV infection in our South Indian population. The prevalence of HBV infection among HIV patients in our study was 6.3%, and this is comparable to the global prevalence (3.6%), 13 as well as Indian HBV prevalence data in the general population (2%-8%). [14] [15] [16] b Anti-HDV was tested for 17 HBV infected, and all occult HBV-infected individuals.
T A B L E 1 Comparison of occult and overt HBV infection T A B L E 2 Predicting occult HBV infection based on serological markers
Marker HBV DNA positive Predicted occult prevalence
Actual occult prevalence
Anti-HBc N = 26 9.6% 10%
Anti-HBs N = 7 2.6% consistent with our data. We saw a decreasing trend of HIV-HBV coinfection compared to the past decade, where the prevalence of HIV-HBV coinfection was 22.2% 22 and 30.4%. 23 We further evaluated the presence of other hepatitis viral infections and found that the prevalence of HBV-HCV coinfection (5.4%) among HIV-positive individuals was slightly higher than other reports from India, where the prevalence ranged from 0 to 2.5%, [24] [25] [26] [27] possibly because all HBV-HCV co-infected individuals were injection drug users. HIV-HBV-HDV infection was found in 35% of our HIV-HBV co-infected participants, which is in line with previous studies from our centre and other centres, where HDV infection among HIV/HBV coinfection was 36%.
28,29
Occult HBV infection is clinically significant, especially in HIVinfected and other immunosuppressed conditions where it can accelerate disease progression. So far, only a few groups have studied occult HBV infection in the Indian population, especially among HIV-infected persons. In this study, we identified occult HBV infection among 10%
of HIV-positive participants. Results from other studies suggest that, occult HBV prevalence among HIV patients ranges widely from 0 to 89% [30] [31] [32] [33] These rates depend on a number of factors like the endemicity of HBV infection, types of NAT used (some studies have used a qualitative assay, which is less sensitive), and using NAT only for antiHBc 34 and anti-HBs 35 positive participants.
We next measured HBeAg, a marker of active HBV replication, among occult HBV participants, and all were negative. However, markers of HBV recovery, anti-HBe and anti-HBs were seen in 6/27 and 7/27 participants, respectively. This indicated a considerable proportion of occult HBV infections may be in the "recovery phase," and follow-up data on these individuals may reveal whether they lose HBV DNA after some time. 36 Pooling NAT has been demonstrated to be a practical and effective means of analysing large numbers of samples for a particular infection where the expected positivity is low 37 . This technique has demonstrated accuracy and cost-effectiveness, as it can reduce the processing and reagent costs. In this study, we adapted a pooling NAT strategy to identify the prevalence of occult HBV infection and to define its test characteristics. We found that, the prevalence of occult HBV infection was 6.7% in pooled NAT (18/270) and 10% by individual sample testing. Test specificity and positive predictive value were both 100% and sensitivity and negative predictive value was 66.7% and 96.4%, respectively. The low sensitivity was likely due to the inability of the ). Of note, these very low levels of HBV DNA detected by individual testing could represent false positivity of the individual testing, but as this was the gold standard of our tests, we cannot be certain. Altogether, the pooling NAT methods would have missed nine cases of occult HBV infection but would have cost 56% less than testing each person individually. Future strategies aimed at increasing sensitivity, such as increasing sample volume and viral concentration before performing pooling NAT, could enhance the sensitivity of the assay.
In conclusion, the prevalence of occult HBV infection among HIV participants was 10%, and the newly developed pooled HBV NAT was highly specific leading to cost savings in our setting, but the sensitivity of this method at low levels of HBV DNA was still low. As conventional HBV viral load assays are expensive and occult HBV infection in the setting of HIV can have severe disease consequences, this pooled NAT method assay should be evaluated further.
